Adverse Events (AEs): Identification, Reporting, and Management Under reporting of harm in clinical trials The Lancet Oncology Adverse Events in Clinical Trials Non Clinical Safety Evaluation and Adverse Events in Phase I Trials Pharmacovigilance Medication Attributable Adverse Events in Heart Failure Trials ScienceDirect Frontiers Evaluating the toxicity profile of combination immune checkpoint inhibitors: a disproportionality analysis of real world adverse events from the FDA Adverse Event Reporting System for tremelimumab, durvalumab, ipilimumab, and nivolumab